Citicoline turns up in spinal cord injury discussions for a reason that is not unreasonable on its face. The compound feeds phosphatidylcholine synthesis, and the secondary damage that follows a spinal cord injury involves membrane breakdown, lipid peroxidation, and glutamate excitotoxicity. A compound that supports membrane repair is a plausible candidate. Plausible is where this stops, though, and the gap between what the research shows and what the research is often said to show is unusually wide here.
Nothing here is medical advice. Citicoline is not approved by the FDA to diagnose, treat, cure, or prevent spinal cord injury or any other condition. Acute spinal cord injury is a surgical and critical care emergency in which the first hours determine outcome, and no supplement has any role in that window. Anyone living with a spinal cord injury should discuss supplements with the physician managing their care, particularly given the medication load common after such an injury.
Key Takeaways
- There are no human trials of citicoline in spinal cord injury. The entire literature is rodent studies and one tissue culture experiment [1][2][3][4]
- Every study used injection, intraperitoneal or intravenous, not an oral capsule. Oral citicoline has never been tested for this indication in any species[1][2][3]
- The rat doses scale to roughly 2.8 grams a day for a 70 kg adult by intravenous infusion, which is a hospital drug protocol and not a supplement regimen[3]
- In most of these studies citicoline was given before or at the moment of injury. That tests prevention. Real patients arrive after the injury has happened[2]
- The model closest to a human motor neuron disease, SOD1-G93A mice, showed no benefit on any endpoint: not survival, not motor function, not motor neuron counts, not myelination[5]
- The regeneration study that reads most impressively gave citicoline together with autologous bone marrow cells, so its results cannot be attributed to citicoline at all[6]
Why the Idea Is Biologically Reasonable
A spinal cord injury unfolds in two phases. The primary injury is the mechanical event itself: the crush, the transection, the vertebral fracture driving bone into cord tissue. Nothing pharmacological touches that; it is over before anyone reaches a hospital. The secondary injury is what follows over hours to weeks, and it is the part that drug research targets. It involves ischemia, oxidative stress, glutamate released from dying cells poisoning the cells next to them, inflammation, and progressive breakdown of neuronal and glial membranes.
Citicoline is a precursor in the pathway that builds phosphatidylcholine, the dominant phospholipid in cell membranes. It has been studied for decades in cerebral ischemia on exactly this logic. Extending that logic from brain to spinal cord is not a stretch; the tissue is the same central nervous system, and the secondary injury cascade looks broadly similar. Researchers made that extension, ran the animal experiments, and published the results. Those results are what this article is about.
The important thing to hold onto is that biological plausibility is where drug development starts, not where it ends. The citicoline literature itself contains a cautionary example: the compound had genuinely compelling preclinical neuroprotection data in stroke, and the large human trials that followed did not reproduce it. A Cochrane review of citicoline in acute ischemic stroke, searching the literature through January 2020, was unable to establish clinical benefit on mortality or disability[7]. Plausibility survived contact with the animals and did not survive contact with patients.
The Weight-Drop Study Compared It to Methylprednisolone
The most cited spinal cord experiment used 60 adult Wistar rats randomized into five groups: laminectomy alone, laminectomy plus injury with no drug, injury plus citicoline, injury plus methylprednisolone, and injury plus both. Injury was produced with a weight-drop model. Some animals were sacrificed at 24 hours for biochemistry and others at six weeks for behavioral and histopathological assessment[1].
The findings were positive. Malondialdehyde and nitric oxide levels were lower and reduced glutathione higher in all three treated groups compared to untreated injury. Trauma size ratios were smaller. Neurological recovery six weeks after surgery was significantly better. The authors’ conclusion was that citicoline is as effective as methylprednisolone, and that combining the two was not superior to either alone[1].
That comparison deserves a moment of context, because it is frequently reported as though methylprednisolone were an unambiguous benchmark. The study describes methylprednisolone as the only pharmacological agent with clinically proven beneficial effects in spinal cord injury, which reflected a widely held view at the time. High-dose steroid protocols in acute spinal cord injury have since become considerably more contested in clinical practice, with the balance of benefit against complications debated for years. Being equivalent to a contested comparator in rats is a weaker result than the sentence sounds.
There is also no dose reported in the study abstract for the citicoline arm, which means anyone quoting this result cannot honestly translate it into a human number. That has not stopped it from being quoted.
The Ischemia Study Dosed Before the Injury
A second rat experiment used a different injury model entirely: ischemic spinal cord injury produced by clamping the aortic arch and subclavian artery through an intrathoracic approach. Forty-two male Sprague-Dawley rats were divided into sham, ischemia, citicoline, ischemic postconditioning, and combined postconditioning plus citicoline groups. Postconditioning meant six cycles of one minute of occlusion followed by five minutes of reperfusion. Apoptotic and antiapoptotic markers, caspase 3, caspase 9, Bax, and Bcl-2, were measured by immunohistochemistry 96 hours after reperfusion[2].
Differences in immunohistochemical scoring were detected, consistent with reduced apoptotic signaling. That is a real finding within its design. The design is the constraint: citicoline was administered intraperitoneally before ischemia was induced[2].
This distinction matters more in spinal cord injury than almost anywhere else. Pre-treatment models answer the question of whether a compound protects tissue that has not yet been damaged. The only humans in a position to be pre-treated for spinal cord ischemia are patients undergoing planned aortic surgery, where cord ischemia is a known operative risk. For traumatic spinal cord injury, which is the overwhelming majority of cases and the one people are actually searching about, pre-treatment is not a clinical scenario that exists. Nobody knows they are about to be in a car accident.
The Only Post-Injury Study Is the Most Informative
One rodent study did give citicoline after the injury, and it is the most relevant of the group for that reason alone. Rat spinal cords were transected at the T1 to T2 level, and CDP-choline was given intravenously at 250 mg/kg either two hours after the injury, 24 hours after, or both[3].
Repeated treatment attenuated the degree of tissue injury. The authors went further and tested whether the effect was explained by the drug’s cardiovascular actions, since spinal cord transection dropped mean arterial pressure and heart rate. It was not: the cardiovascular changes did not track the protection, and the authors attributed the effect instead to reduced oxidative stress[3].
That is a well-constructed experiment, and it is genuinely the strongest entry in this literature. It is still a rat, and the dose is worth converting. Using standard body surface area scaling between species, 250 mg/kg in a rat corresponds to roughly 40 mg/kg in a human, which is about 2.8 grams for a 70 kg adult. Given intravenously. Common citicoline capsules contain 250 or 500 mg, and human oral trials generally run 500 to 2,000 mg per day. The animal protocol is a different intervention from the one on a supplement shelf, not a smaller version of it.
The Motor Neuron Result Nobody Quotes
The single most useful study in this entire cluster is the one that found nothing. Researchers gave CDP-choline or vehicle daily by intraperitoneal injection to transgenic SOD1-G93A mice, the standard model of amyotrophic lateral sclerosis, starting at day 30, before disease onset. They monitored survival, motor function, weight, and general condition, and ran histology for motor neuron survival, astrocytosis, and myelination in the spinal cord[5].
Nothing moved. Deterioration of general condition was unchanged. Weight loss was unchanged. Survival was not prolonged. No behavioral motor function test showed a difference. Histology showed no difference in motor neuron survival, astrocytosis, or myelination. The authors concluded that their data do not strongly support further clinical validation of CDP-choline for ALS[5].
This is worth dwelling on because of what the study had going for it. The treatment started before disease onset, which is the most favorable possible timing. The endpoints included the exact spinal cord motor neuron measures that the positive studies reported improving. The rationale was the same anti-excitotoxic and membrane-preserving mechanism cited everywhere else. A negative result under favorable conditions carries more information than a positive result under favorable conditions, and this one is essentially absent from consumer-facing writing about citicoline and the spinal cord.
There is a parallel in vitro study, in organotypic cultures of rat lumbar spinal cord exposed to a glutamate transport blocker, where CDP-choline pretreatment reduced apoptotic changes in motor neurons. Read carefully, even that positive result is partial: the authors specify that necrotic and autophagocytic motor neuron injury still occurred[4]. Citicoline shifted one death pathway in a dish and left the others intact.
The Regeneration Study Cannot Be Attributed to Citicoline
One further study is often cited as evidence for spinal cord regeneration. It investigated autologous bone marrow modulated with neurotransmitters and with citicoline in spinal cord injured rats, using radioreceptor assays, real-time PCR for muscarinic M1 receptor gene expression, and confocal microscopy. Muscarinic M1 receptor binding and expression were significantly reduced after injury and significantly reversed toward control values in both treatment groups[6].
The treatment groups are the issue. One received serotonin and GABA together with bone marrow; the other received citicoline together with bone marrow[6]. There is no citicoline-alone arm and no bone-marrow-alone arm. Autologous bone marrow cell transplantation is itself an active experimental intervention in spinal cord injury, and it is entirely possible that the bone marrow did the work. The study cannot distinguish these possibilities and does not claim to. Anyone presenting it as evidence that citicoline regenerates spinal cord tissue is reporting something the experiment was not built to show.
What This Means in Practice
For acute spinal cord injury, the answer is straightforward. It is a time-critical emergency in which imaging, blood pressure management, spinal stabilization, and often surgical decompression determine outcome. There is no supplement question in that setting, and the interval in which the animal studies delivered their benefit, two hours after injury by intravenous infusion, is an interval spent in an emergency department.
For someone living with an established spinal cord injury, the question is different but the evidence is no better. Every study described here targeted the acute or subacute phase. None examined chronic injury, functional recovery over months and years, neuropathic pain, spasticity, bladder function, or any of the outcomes that actually shape daily life after a spinal cord injury. The literature simply does not address that population.
None of this makes citicoline a dangerous thing to take. Its human safety record across other indications is reasonable at typical supplement doses. But a compound being safe is not the same as it being useful, and the specific claim that citicoline helps spinal cord injury rests on rats given injections, frequently before the injury, in studies whose closest human analogue produced a flat negative. That is worth knowing before spending money on it for this reason, and worth raising with a physician rather than deciding alone, since post-injury medication regimens are often complex.
Frequently Asked Questions
Are there human trials of citicoline for spinal cord injury?
No. As of this writing the published literature consists of rodent studies and one tissue culture experiment. No randomized controlled trial, no observational cohort, and no case series in humans with spinal cord injury has been published.
Did citicoline work as well as steroids in the animal study?
In one 60-rat weight-drop study the authors concluded citicoline was as effective as methylprednisolone on oxidative stress markers, lesion size, and neurological recovery at six weeks, and that combining them was not superior to either alone. That comparison is to a drug whose role in human spinal cord injury has itself become contested, and the study reports no citicoline dose in its abstract.
What dose did the animal studies use?
The best-designed post-injury study used 250 mg/kg intravenously in rats. Scaled between species by body surface area, that corresponds to roughly 40 mg/kg in a human, or about 2.8 grams a day for a 70 kg adult, delivered intravenously. Typical capsules contain 250 to 500 mg taken by mouth.
Why does it matter when the citicoline was given?
Because most of these studies dosed before or at the moment of the injury, which tests prevention rather than treatment. Outside of planned aortic surgery, no human can be pre-treated for a spinal cord injury. Only one study dosed after the injury, at two and 24 hours, and it is the most clinically relevant of the group for that reason.
What happened in the ALS mouse study?
Nothing measurable. CDP-choline given daily from before disease onset in SOD1-G93A mice did not change general condition, weight loss, or survival, produced no difference on any motor function test, and showed no effect on motor neuron survival, astrocytosis, or myelination in the spinal cord. The authors concluded the data do not support further clinical validation.
Should I take citicoline for an existing spinal cord injury?
That is a conversation for the physician managing your care, not a decision to make from this literature. No study has examined chronic spinal cord injury, functional recovery over the long term, neuropathic pain, or spasticity, and people living with spinal cord injury often take multiple medications where interactions matter.
References
- Yücel N, et al. Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery. Neurochemical Research (2006). PMID 16794862
- Turkkan A, et al. Citicoline and postconditioning provides neuroprotection in a rat model of ischemic spinal cord injury. Acta Neurochirurgica (2010). PMID 20112033
- Coskun C, et al. Effect of repeatedly given CDP-choline on cardiovascular and tissue injury in spinal shock conditions: investigation of the acute phase. Journal of Pharmacy and Pharmacology (2010). PMID 20604840
- Matyja E, et al. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Folia Neuropathologica (2008). PMID 18587708
- Knippenberg S, et al. CDP-choline is not protective in the SOD1-G93A mouse model of ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2013). PMID 23286744
- Paulose CS, et al. Spinal cord regeneration by modulating bone marrow with neurotransmitters and Citicholine: Analysis at micromolecular level. Biomedical Journal (2017). PMID 28521906
- Martí-Carvajal AJ, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database of Systematic Reviews (2020). PMID 32860632
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
